FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892400856> ?p ?o ?g. }

• W2892400856 endingPage "259" @default.
• W2892400856 startingPage "251" @default.
• W2892400856 abstract "<b><i>Background:</i></b> Anemia is one of the most prevalent complications in patients with chronic kidney disease, which is believed to be caused by the insufficient synthesis of erythropoietin by the kidney. This phase III study aimed to compare the efficacy and safety of CinnaPoietin® (epoetin beta, CinnaGen) with Eprex® (epoetin alfa, Janssen Cilag) in the treatment of anemia in ESRD hemodialysis patients. <b><i>Methods:</i></b> In this randomized, active-controlled, double-blind, parallel, and non-inferiority trial, patients were randomized to receive either CinnaPoietin® or Eprex® for a 26-week period. The primary endpoints of this study were to assess the mean hemoglobin (Hb) change during the last 4 weeks of treatment from baseline along with the evaluation of the mean weekly epoetin dosage per kilogram of body weight that was necessary to maintain the Hb level within 10–12 g/dL during the last 4 weeks of treatment. As the secondary objective, safety was assessed along with other efficacy endpoints. <b><i>Results:</i></b> A total of 156 patients were included in this clinical trial. There was no statistically significant difference between treatment groups regarding the mean Hb change (<i>p</i> = 0.21). In addition, the mean weekly epoetin dosage per kg of body weight for maintaining the Hb level within 10–12 g/dL showed no statistically significant difference between treatment arms (<i>p</i> = 0.63). Moreover, both products had comparable safety profiles. However, the incidence of Hb levels above 13 g/dL was significantly lower in the CinnaPoietin® group. <b><i>Conclusion:</i></b> CinnaPoietin® was proved to be non-inferior to Eprex® in the treatment of anemia in ESRD hemodialysis patients. The trial was registered in Clinicaltrials.gov (NCT03408639)." @default.
• W2892400856 created "2018-10-05" @default.
• W2892400856 creator A5000780764 @default.
• W2892400856 creator A5005197147 @default.
• W2892400856 creator A5012188731 @default.
• W2892400856 creator A5030520373 @default.
• W2892400856 creator A5051639847 @default.
• W2892400856 creator A5071444923 @default.
• W2892400856 creator A5072204702 @default.
• W2892400856 creator A5072658334 @default.
• W2892400856 creator A5074111470 @default.
• W2892400856 date "2018-01-01" @default.
• W2892400856 modified "2023-10-16" @default.
• W2892400856 title "Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients" @default.
• W2892400856 cites W103389783 @default.
• W2892400856 cites W1578634351 @default.
• W2892400856 cites W1975789579 @default.
• W2892400856 cites W1991603503 @default.
• W2892400856 cites W1995563191 @default.
• W2892400856 cites W2033803279 @default.
• W2892400856 cites W2046124938 @default.
• W2892400856 cites W2058083047 @default.
• W2892400856 cites W2087384142 @default.
• W2892400856 cites W2091843730 @default.
• W2892400856 cites W2097511323 @default.
• W2892400856 cites W2109230674 @default.
• W2892400856 cites W2120939456 @default.
• W2892400856 cites W2135454486 @default.
• W2892400856 cites W2140813176 @default.
• W2892400856 cites W2584947097 @default.
• W2892400856 cites W2610637512 @default.
• W2892400856 cites W2995679582 @default.
• W2892400856 cites W66506442 @default.
• W2892400856 cites W3149132779 @default.
• W2892400856 doi "https://doi.org/10.1159/000493097" @default.
• W2892400856 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6381861" @default.
• W2892400856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30253403" @default.
• W2892400856 hasPublicationYear "2018" @default.
• W2892400856 type Work @default.
• W2892400856 sameAs 2892400856 @default.
• W2892400856 citedByCount "9" @default.
• W2892400856 countsByYear W28924008562019 @default.
• W2892400856 countsByYear W28924008562021 @default.
• W2892400856 countsByYear W28924008562023 @default.
• W2892400856 crossrefType "journal-article" @default.
• W2892400856 hasAuthorship W2892400856A5000780764 @default.
• W2892400856 hasAuthorship W2892400856A5005197147 @default.
• W2892400856 hasAuthorship W2892400856A5012188731 @default.
• W2892400856 hasAuthorship W2892400856A5030520373 @default.
• W2892400856 hasAuthorship W2892400856A5051639847 @default.
• W2892400856 hasAuthorship W2892400856A5071444923 @default.
• W2892400856 hasAuthorship W2892400856A5072204702 @default.
• W2892400856 hasAuthorship W2892400856A5072658334 @default.
• W2892400856 hasAuthorship W2892400856A5074111470 @default.
• W2892400856 hasBestOaLocation W28924008561 @default.
• W2892400856 hasConcept C126322002 @default.
• W2892400856 hasConcept C126894567 @default.
• W2892400856 hasConcept C141071460 @default.
• W2892400856 hasConcept C168563851 @default.
• W2892400856 hasConcept C203092338 @default.
• W2892400856 hasConcept C2776164570 @default.
• W2892400856 hasConcept C2778063415 @default.
• W2892400856 hasConcept C2778248108 @default.
• W2892400856 hasConcept C2778534260 @default.
• W2892400856 hasConcept C2778653478 @default.
• W2892400856 hasConcept C2778917026 @default.
• W2892400856 hasConcept C535046627 @default.
• W2892400856 hasConcept C71924100 @default.
• W2892400856 hasConcept C90924648 @default.
• W2892400856 hasConceptScore W2892400856C126322002 @default.
• W2892400856 hasConceptScore W2892400856C126894567 @default.
• W2892400856 hasConceptScore W2892400856C141071460 @default.
• W2892400856 hasConceptScore W2892400856C168563851 @default.
• W2892400856 hasConceptScore W2892400856C203092338 @default.
• W2892400856 hasConceptScore W2892400856C2776164570 @default.
• W2892400856 hasConceptScore W2892400856C2778063415 @default.
• W2892400856 hasConceptScore W2892400856C2778248108 @default.
• W2892400856 hasConceptScore W2892400856C2778534260 @default.
• W2892400856 hasConceptScore W2892400856C2778653478 @default.
• W2892400856 hasConceptScore W2892400856C2778917026 @default.
• W2892400856 hasConceptScore W2892400856C535046627 @default.
• W2892400856 hasConceptScore W2892400856C71924100 @default.
• W2892400856 hasConceptScore W2892400856C90924648 @default.
• W2892400856 hasIssue "4" @default.
• W2892400856 hasLocation W28924008561 @default.
• W2892400856 hasLocation W28924008562 @default.
• W2892400856 hasLocation W28924008563 @default.
• W2892400856 hasLocation W28924008564 @default.
• W2892400856 hasOpenAccess W2892400856 @default.
• W2892400856 hasPrimaryLocation W28924008561 @default.
• W2892400856 hasRelatedWork W1588725841 @default.
• W2892400856 hasRelatedWork W2093825344 @default.
• W2892400856 hasRelatedWork W2098254080 @default.
• W2892400856 hasRelatedWork W2099453712 @default.
• W2892400856 hasRelatedWork W2110697185 @default.
• W2892400856 hasRelatedWork W2159063843 @default.
• W2892400856 hasRelatedWork W2179797810 @default.
• W2892400856 hasRelatedWork W2241867744 @default.

• next